NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Aldeyra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. Why is Aldeyra Therapeutics being Investigated? Aldeyra Therapeutics is a biotechnology company focused o ...

NEW YORK, April 19, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. Why is Aldeyra Therapeutics being Investigated? Aldeyra Therapeutics is a biotechnology company focused o ...

NEW YORK, April 14, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Aldeyra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On April 3, 2 ...

NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you invested in Aldeyra Therapeutics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/aldeyra-therapeutics-inc. Why is Aldeyra Therapeutics being Investigated? Aldeyra Therapeutics is a biotechnology company focused o ...

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Aldeyra Therapeutics for possible violations of federal securities laws and unlawful business practices [1] - Aldeyra received a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, indicating that the application failed to demonstrate efficacy in treating dry eye disease and requires additional studies [2] Company Summary - Aldeyra Therapeutics is facing scrutiny after the FDA's response highlighted concerns about the efficacy of reproxalap, which may impact the company's stock performance [2] - The FDA's letter pointed out methodological issues in the trial data submitted, which could have affected the interpretation of results [2] Legal and Investor Relations - The law firm is reaching out to Aldeyra stockholders who may have suffered losses and is encouraging them to participate in the investigation [3] - Bragar Eagel & Squire, P.C. specializes in representing investors in complex litigation, indicating a focus on protecting shareholder rights [4]

SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter ("CRL") from the FDA for the resubmission of the New Drug Application ("NDA") of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. This stark regulatory rejection, which contradicted Aldeyra's repeated assurances of imminent approval, erased ...

SAN FRANCISCO, April 09, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter (“CRL”) from the FDA for the resubmission of the New Drug Application (“NDA”) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease.   This stark regulatory rejection, which contradicted Aldeyra’s repeated assurances of imminent approval, e ...

Core Insights - Aldeyra Therapeutics is under investigation by Kirby McInerney LLP for potential violations of federal securities laws and unlawful business practices [1][3] - The FDA issued a Complete Response Letter for Aldeyra's New Drug Application for reproxalap, indicating that the application did not demonstrate efficacy in treating ocular symptoms associated with dry eyes [3] - Following the FDA's announcement, Aldeyra's stock price plummeted by approximately 73%, dropping from $5.32 to $1.42 per share [3] Company Developments - The investigation by Kirby McInerney LLP focuses on whether Aldeyra and its officers engaged in unlawful practices [1] - The FDA's concerns regarding the NDA included methodological issues and differences in baseline scores across treatment arms [3] - The significant decline in share price reflects investor reaction to the FDA's findings and the implications for Aldeyra's lead drug candidate [3]

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Aldeyra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Ap ...